Art. -Nr.: HY-123606

GSK484

54 Cited Publications

Kundenbewertung

Based on 54 publication(s) in Google Scholar

GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8⁺ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.14%
CAS. Nr.: 1652629-23-6
Formel: C₂₇H₃₁N₅O₃
Molecular Weight:473.57

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

GSK484 Chemical Structure

CAS. Nr.: 1652629-23-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (54)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle MHC Isoform-spezifische Produkte anzeigen :

MHC I
MHC II

In Vitro

GSK484 (10 μM; 6 h) inhibits the expression of citrullinated histone H3, HLA class I (MHC-I), HLA-A2 induced by Erastin (HY-15763) in human rheumatoid arthritis fibroblast-like synoviocytes; in the co-culture system of human rheumatoid arthritis fibroblast-like synoviocytes and CD8+ T cells, it suppresses the activation, proliferation and inflammatory cytokine release of CD8+ T cells^[1].
GSK484 inhibits the ferroptosis-upregulated expression of PAD4 and the associated inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)^[2].
GSK484 (10 μM) completely abolishes heme/TNFα-induced mast cell extracellular trap (mast cell extracellular trap, MCET) formation in mast cells isolated from the dorsal skin of homozygous BERK sickle cell (HbSS) mice^[3].
Pretreatment with GSK484 (10 μM) for 2 hours before hypoxia maintains intracellular ATP levels in primary cultured neonatal wild-type mouse cardiomyocytes at 4 h of reoxygenation, and improves their metabolic activity at 20 h of reoxygenation. In contrast, administration of GSK484 at the onset of reoxygenation only improves metabolic activity at 20 h of reoxygenation, but fails to maintain ATP levels^[4].
GSK484 (10 μM; 15 min pre-treatment) potently inhibits extracellular DNA production and H3Cit⁺ neutrophil formation induced by Ionomycin (HY-13434) in human neutrophils after 3 h of stimulation; however, it exerts no such effect on neutrophils stimulated with PMA (HY-18739) or isolated from patients with SCD^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[1]

Cell Line:

Rheumatoid arthritifibroblast-like synoviocytes (RA-FLs)
Concentration:

10 μM
Incubation Time:

6 h; with or without the ferroptosis activator Erastin (HY-15763) (0, 2.5, 5, or 7.5 μM) or the Fer-1 (HY-100579) (0, 5, 10, or 15 μM) for 48 h
Result:

Inhibited erastin-induced increase in HLA-I.
Inhibited erastin-induced T cell activation marker expression increase.

Parmacokinetics

Species	Dose	Route	T_1/2	CL_blood
Mice^[6]	4 mg/kg	i.p.	3.8 h	19 mL/min/kg

In Vivo

GSK484 (10 mg/kg; i.p.; 3 times per week; 6 total administrations) inhibits joint inflammation, bone destruction, synovial hyperplasia, and expression of inflammatory markers exacerbated by Erastin (HY-15763) in CIA mice, and alleviates the pathological effects caused by enhanced ferroptosis in this disease model^[1].
GSK484 (10 mg/kg; i.p.; 3 times per week; 6 total administrations) reduces joint inflammation and bone destruction in CIA mice, reverses intestinal dysbiosis, restores metabolic profiles to normal, and alleviates the deterioration of RA-related pathologies induced by Erastin (HY-15763)^[2].
GSK484 (20 mg/kg; s.c.; daily; 30 d) produces sustained inhibition of neuropathic hyperalgesia in homozygous BERK sickle cell mice, while exerting extensive anti-inflammatory and hematological benefits without the development of analgesic tolerance^[3].
GSK484 (10 μM; single dose; 30 minutes prior to thrombus induction) significantly prolongs the blood flow cessation time of cerebral arterioles and venules in C57BL/6 mice in a light-activated thrombosis model, and significantly increases the blood flow cessation time of cerebral arterioles and venules in sickle cell transgenic mice^[5].
GSK484 (4 mg/kg; i.p.; once every 2 days; 9 d) significantly reduces the density of neutrophil extracellular traps (NETs) in the colonic mucosa of mice with colitis induced by 2% (w/v) DSS (HY-116282C) (36-50 kd), but fails to improve clinical or inflammatory disease biomarkers^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

DBA/1J mice with Rheumatoid arthritis (male, 8 weeks old, 21±2 g, SPF grade, collagen-induced arthritis model)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; three times a week; total of 6 times
Result:

Inhibited erastin-exacerbated paw inflammation and reduced paw thickness compared to erastin-only treatment.
Inhibited erastin-exacerbated bone destruction, with micro-CT showing reduced joint damage relative to erastin-only treatment.
Reduced erastin-increased joint inflammation scores, bone erosion scores, and synovial hyperplasia scores via histological scoring.
Reduced erastin-increased MHC-I, citrullinated histone H3 (cit-h3), PAD4, CD8, TNF-α, and IFN-γ positive cell percentages in joint tissue via immunohistochemical analysis.

Animal Model:

homozygous BERK sickle (HbSS) mcie with Sickle cell disease^[3]
Dosage:

20 mg/kg
Administration:

s.c.; daily; 30 days
Result:

Significantly reduced cold hyperalgesia at 48 hours.
Significantly reduced heat hyperalgesia at 72 hours.
Significantly reduced mechanical hyperalgesia after 1 week with attenuation persisting through 30 days and no analgesic tolerance observed.
Decreased skin mast cell degranulation by 90%.
Significantly reduced white blood cell counts.
Significantly reduced serum GM-CSF levels.
Significantly increased hematocrit.
Reduced skin levels of inflammatory cytokines CCL2/MCP-1, TNFα, and RANTES by approximately 50% relative to baseline/control groups.

Animal Model:

Cerebrovascular thrombosis model in C57BL/6 mice (male and female, 8-10 weeks of age), Townes mice (male and female, 8-10 weeks of age, sickle transgenic)^[5]
Dosage:

10 μM
Administration:

single dose (30 minutes prior to thrombosis induction)
Result:

Significantly prolonged blood flow cessation time in both cerebrovascular arterioles and venules compared to vehicle-treated mice (C57BL/6).
Significantly increased blood flow cessation time in both cerebrovascular arterioles and venules compared to vehicle-treated mice (Townes), with a mean flow cessation time of ~28 minutes in arterioles and ~21 minutes in venules.

Animal Model:

C57BL/6 mice with Inflammatory bowel disease (male, 7 weeks of age at study start, 2% w/v DSS-induced colitis)^[6]
Dosage:

4 mg/kg
Administration:

i.p.; every second day; 9 days
Result:

Significantly diminished colonic mucosal neutrophil extracellular trap (NET) density to levels similar to control mice.
Did not improve disease activity index scores, weight loss, colon length, colon weight/length ratio, fecal hemoglobin levels, or colonic/faecal calprotectin levels compared to DSS-only treated mice.
Did not reduce DSS-induced colon histoarchitectural damage, goblet cell loss, or mast cell density, nor alter levels of inflammatory cytokines IL-1β, IL-4, or IL-10.
Caused a statistically significant reduction in total superoxide dismutase (SOD) activity in colonic tissue.
Had no effect on catalase activity, Nrf2, GPx4, or SOD1 protein expression, or colonic lipid peroxidation.

Chemical Information

CAS. Nr. 1652629-23-6
Appearance Solid
Molecular Weight 473.57
Formel C₂₇H₃₁N₅O₃
Color White to off-white
SMILES

O=C(N1C[C@H](N)[C@H](O)CC1)C2=CC(OC)=C3C(N=C(C(N4CC5CC5)=CC6=C4C=CC=C6)N3C)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (54)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cancer Cell

DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. [Abstract]

2025 Sep 8;43(9):1758-1775.e8. PMID: 40816293

GSK484 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Sep 8;43(9):1758-1775.e8. [Abstract]

Schema for GSK484 treatment protocol and summary tumor growth curves of MC38 in Dnase1l3fl/fl and Dnase1l3cko mice (n = 7).
Cancer Cell

Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. [Abstract]

2021 Mar 8;39(3):423-437.e7. PMID: 33450198

GSK484 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are BLI quantification of primary tumor growth at day 19.

GSK484 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are BLI quantification of lung metastasis at week 5.

GSK484 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are pulmonary surface nodules at week 5.

GSK484 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are NET formation in lung metastases.
Immunity

The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. [Abstract]

2023 Dec 12;56(12):2755-2772.e8. PMID: 38039967
Immunity

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. [Abstract]

2020 May 19;52(5):856-871.e8. PMID: 32289253
Cancer Commun (Lond)

2025 Dec 15.
Cell Mol Immunol

Neutrophil ALDH2 is a new therapeutic target for the effective treatment of sepsis-induced ARDS. [Abstract]

2024 May;21(5):510-526. PMID: 38472357
Adv Funct Mater

2025 Aug 3.
Nat Commun

Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus. [Abstract]

2023 Feb 16;14(1):872. PMID: 36797275
J Adv Res

PAD4-mediated citrullination of IGF2BP2 stabilizes MCM mRNAs to drive intrahepatic cholangiocarcinoma progression. [Abstract]

2026 Jun 5:S2090-1232(26)00460-1. PMID: 42250722
Mol Cell

Targeted citrullination enables p53 binding to non-canonical sites. [Abstract]

2025 Oct 2;85(19):3588-3604.e11. PMID: 41043392
Adv Sci (Weinh)

Bifidobacterium Breve Yang08 Alleviates Atopic Dermatitis By Enriching Akkermansia Muciniphila and Inhibiting Neutrophil Extracellular Traps Formation In Mice. [Abstract]

2026 Apr;13(20):e18588. PMID: 41655253
Adv Sci (Weinh)

Succinate Dehydrogenase Subunit A (SDHA) Mediated Microglia Extracellular Traps Formation Participating in Cerebral Ischemic Reperfusion Injury. [Abstract]

2025 Aug 20:e11873. PMID: 40832885
Adv Sci (Weinh)

The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers. [Abstract]

2025 Jul 21:e00950. PMID: 40686457
Adv Sci (Weinh)

NETs-CD44-IL-17A Feedback Loop Drives Th17-Mediated Inflammation in Behçet's Uveitis. [Abstract]

2025 Apr;12(16):e2411524. PMID: 40013981
Adv Sci (Weinh)

ACSL1 Aggravates Thromboinflammation by LPC/LPA Metabolic Axis in Hyperlipidemia Associated Myocardial Ischemia-Reperfusion Injury. [Abstract]

2025 Mar;12(11):e2406359. PMID: 39853712
Adv Sci (Weinh)

Neutrophil-Mediated Tumor-Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy. [Abstract]

2023 Oct;10(29):e2301835. PMID: 37565362
Cell Death Differ

EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction. [Abstract]

2026 Jan 15. PMID: 41540251
Research (Wash D C)

Neuromodulation and Copper Chelation Reverse Sleep Fragmentation-Aggravated Myocardial Ischemia-Reperfusion Injury by Targeting NET-Induced Endothelial Cuproptosis. [Abstract]

2026 May 8:9:1266. PMID: 42109881
Pharmacol Res

Targeting P2RX1 alleviates renal ischemia/reperfusion injury by preserving mitochondrial dynamics. [Abstract]

2021 Aug:170:105712. PMID: 34091010
J Immunother Cancer

Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis. [Abstract]

2024 Jun 26;12(6):e009082. PMID: 38926151
Phytomedicine

Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis. [Abstract]

2026 Aug:158:158386. PMID: 42275874
Diabetologia

Intestinal neutrophil extracellular traps promote gut barrier damage exacerbating endotoxaemia, systemic inflammation and progression of diabetic retinopathy in type 2 diabetes. [Abstract]

2025 Apr;68(4):866-889. PMID: 39875729
J Tissue Eng

Formation of neutrophil extracellular traps in the early stages exacerbate the healing process by regulating macrophage polarization in Achilles tendon-bone injury. [Abstract]

2025 Aug 19:16:20417314251348038. PMID: 40843411
Apoptosis

Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression. [Abstract]

2023 Oct;28(9-10):1484-1495. PMID: 37368176
Cell Rep

Inappropriate use of antibiotics exacerbates inflammation through OMV-induced pyroptosis in MDR Klebsiella pneumoniae infection. [Abstract]

2021 Sep 21;36(12):109750. PMID: 34551309
Br J Pharmacol

Neutrophil extracellular traps drive tubulointerstitial fibrosis via the coiled-coil domain-containing protein 25 (CCDC25)-Yes-associated protein 1 (YAP1) axis-mediated autophagy regulation. [Abstract]

2026 May 27. PMID: 42204873
Front Immunol

Reduced Neutrophil Extracellular Trap Formation During Ischemia Reperfusion Injury in C3 KO Mice: C3 Requirement for NETs Release. [Abstract]

2022 Feb 16:13:781273. PMID: 35250972
JCI Insight

HMGB1-mediated formation of IL-33-abundant NETs drives lung-to-kidney injury in severe pneumonia-associated acute kidney injury. [Abstract]

2026 May 22;11(10):e191979. PMID: 42171612
JCI Insight

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination. [Abstract]

2026 Feb 3:e199307. PMID: 41632530
OncoImmunology

Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells. [Abstract]

2022 Mar 16;11(1):2052418. PMID: 35309732
Int Immunopharmacol

The natural compound PEITC ameliorates imiquimod-induced psoriasis in mice by suppressing neutrophil extracellular traps formation. [Abstract]

2025 Jun 26:159:114939. PMID: 40414074
Int Immunopharmacol

Berberine regulates PADI4-related macrophage function to prevent lung cancer. [Abstract]

2022 Sep:110:108965. PMID: 35764017
Int Immunopharmacol

Protectin D1 decreases pancreatitis severity in mice by inhibiting neutrophil extracellular trap formation. [Abstract]

2021 May:94:107486. PMID: 33639566
Front Cell Infect Microbiol

Veillonella parvula outer membrane vesicles increase ICAM-1+ neutrophils exhibiting elevated NET formation via ROS-PAD4 signaling. [Abstract]

2025 Jun 11:15:1540634. PMID: 40568695
Mucosal Immunol

PAD4 inhibition impacts immune responses in SARS-CoV-2 infection. [Abstract]

2025 Apr 19:S1933-0219(25)00044-3. PMID: 40258416
J Thromb Haemost

NETs induce persistent lung tissue damage via thromboinflammation without altering virus resolution in a mouse coronavirus model. [Abstract]

2024 Jan;22(1):188-198. PMID: 37748582
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Transl Stroke Res

Neutrophil Extracellular Traps Induce Brain Edema Around Intracerebral Hematoma via ERK-Mediated Regulation of MMP9 and AQP4. [Abstract]

2024 Dec 28. PMID: 39733198
FEBS J

Neutrophil extracellular traps boost laser-induced mouse choroidal neovascularization through the activation of the choroidal endothelial cell TLR4/HIF-1α pathway. [Abstract]

2023 Nov;290(22):5395-5410. PMID: 37552110
Transl Stroke Res

Neutrophil Extracellular Traps may be a Potential Target for Treating Early Brain Injury in Subarachnoid Hemorrhage. [Abstract]

2022 Feb;13(1):112-131. PMID: 33852132
Parasit Vectors

Pentatrichomonas hominis induces extracellular traps formation of macrophages via the TLR2/NADPH/PAD4 pathway. [Abstract]

2025 Jul 1;18(1):248. PMID: 40598534
Kidney Dis (Basel)

Clinical and Experimental Insights into the Role of NETosis in IgA Nephropathy Pathogenesis. [Abstract]

2025 May 9;11(1):450-468. PMID: 40606676
Fitoterapia

Er Miao San and its main components phellodendrine and atractylenolide-I exert anti-rheumatoid arthritis effects by inhibiting PAD4 and thereby reducing the formation of NETs. [Abstract]

2025 Sep:185:106771. PMID: 40738459
Vet Microbiol

The PERK-eIF2α branch activates the NLRP3 inflammasome through the NF-κB signaling pathway to suppress NDV replication. [Abstract]

2026 May:316:110968. PMID: 41793984
Physiol Res

Targeting the Toll-Like Receptor 4 Ameliorates Heart Failure in Aged Mice by Inhibiting the Formation of Neutrophil Extracellular Traps. [Abstract]

2026 Mar 11;75(1):29-43. PMID: 41811699
STAR Protoc

Protocol for identification of protein citrullination by immunoprecipitation followed by mass spectrometry. [Abstract]

2026 Jan 12;7(1):104326. PMID: 41528850
Hlife

2026 Mar 18.
bioRxiv

2025 Sep 5.
bioRxiv

APOE Protects Against Severe Infection with Mycobacterium tuberculosis by Restraining Production of Neutrophil Extracellular Traps. [Abstract]

2024 Oct 4:2024.10.04.616580. PMID: 39605723
bioRxiv

2024 July 01.
Sci Tradit Chin Med

2023 Sep 20.
Research Square Preprint

2023 May 11.
bioRxiv

2023 Apr 3.
Aging Cell

Kindlin-3 in platelets and myeloid cells differentially regulates deep vein thrombosis in mice. [Abstract]

2019 Aug 31;11(17):6951-6959. PMID: 31477636

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (105.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1116 mL

10.5581 mL

21.1162 mL

5 mM

0.4223 mL

2.1116 mL

4.2232 mL

10 mM

0.2112 mL

1.0558 mL

2.1116 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu X, et al. Ferrostatin-1 reduces the inflammatory response of rheumatoid arthritis by decreasing the antigen presenting function of fibroblast-like synoviocytes. J Transl Med. 2025;23(1):280. Published 2025 Mar 6. [Content Brief]

[2]. Zhu X, et al. Ferroptosis Induces gut microbiota and metabolic dysbiosis in Collagen-Induced arthritis mice via PAD4 enzyme. Gene. 2025;936:149106. [Content Brief]

[3]. Tran H, et al. Critical Role of Protein Arginine Deiminase 4 in Mast Cell Extracellular Trap Formation Leading to Neuropathic Pain in Sickle Mice[J]. Blood, 2017, 130: 439.

[4]. Mand M, et al. Peptidylarginine deiminase 4 deficiency alleviates hypoxia/reoxygenation-induced cardiomyocyte injury. PLoS One. 2025;20(9):e0330864. Published 2025 Sep 10. [Content Brief]

[5]. Ansari J, et al. Regulating Neutrophil PAD4/NOX-Dependent Cerebrovasular Thromboinflammation. Int J Biol Sci. 2023;19(3):852-864. Published 2023 Jan 9. [Content Brief]

[6]. Xie K, et al. The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis. Biosci Rep. Published online May 20, 2025. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1116 mL	10.5581 mL	21.1162 mL	52.7905 mL
	5 mM	0.4223 mL	2.1116 mL	4.2232 mL	10.5581 mL
	10 mM	0.2112 mL	1.0558 mL	2.1116 mL	5.2791 mL
	15 mM	0.1408 mL	0.7039 mL	1.4077 mL	3.5194 mL
	20 mM	0.1056 mL	0.5279 mL	1.0558 mL	2.6395 mL
	25 mM	0.0845 mL	0.4223 mL	0.8446 mL	2.1116 mL
	30 mM	0.0704 mL	0.3519 mL	0.7039 mL	1.7597 mL
	40 mM	0.0528 mL	0.2640 mL	0.5279 mL	1.3198 mL
	50 mM	0.0422 mL	0.2112 mL	0.4223 mL	1.0558 mL
	60 mM	0.0352 mL	0.1760 mL	0.3519 mL	0.8798 mL
	80 mM	0.0264 mL	0.1320 mL	0.2640 mL	0.6599 mL
	100 mM	0.0211 mL	0.1056 mL	0.2112 mL	0.5279 mL

Keywords

GSK484

54 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GSK484

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cardiovascular Disease Compound Library

Chemical Probe Library

Coagulation and Anti-coagulation Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) GSK484

Alle MHC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (54)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GSK484

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cardiovascular Disease Compound Library

Chemical Probe Library

Coagulation and Anti-coagulation Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) GSK484

Alle MHC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (54)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GSK484 Related Classifications

HY-123606 Related Classifications